Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee options vest over time, with each installment dependent on continued employment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunic (Nasdaq: IMUX) granted inducement stock options covering 196,350 common shares to seven new employees between September 14 and September 28, 2026.
The Compensation Committee approved the awards under the 2026 Inducement Equity Compensation Plan as an inducement to begin employment, pursuant to Nasdaq Listing Rule 5635(c)(4). For each employee, 25% of the options vest on the first anniversary of the applicable hire date. The remainder vest monthly in 36 equal installments, with each vesting date subject to continued employment.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 196,350 common shares granted to seven new employees create potential shareholder dilution.
Key Figures
- Options covering common shares
- 196,350 shares
- Aggregate inducement grants to new employees
- Recipients
- 7 employees
- New employees receiving inducement grants
- Initial vesting
- 25%
- Vests on the first anniversary of each recipient's hire date
- Remaining vesting installments
- 36 equal monthly installments
- Subject to continued employment on each vesting date
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
nurr1 activator medical
dihydroorotate dehydrogenase (dhodh) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com
US Media Contact
Real Chemistry
media@imux.com
/PRNewswire -- Sept. 29, 2026/
SOURCE Immunic, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many inducement stock options did Immunic grant to new employees?
Immunic granted options covering 196,350 common shares to seven new employees between September 14 and September 28, 2026, under its 2026 Inducement Equity Compensation Plan.
What is the vesting schedule for Immunic's September 2026 inducement options?
25% vest on the first anniversary of each employee's applicable hire date, and the remainder vest monthly in 36 equal installments. Each installment is subject to the employee's continued employment on the vesting date.